MYC and lung carcinoma: Our current findings indicate that the pre-selection of patients with tumours in which any of the MYC family of genes have been genetically activated will have better response rates to SAHA, which suggests that SAHA could be used to treat neuroblastomas and lung cancers, among other types of cancer, in which the MYC genes are amplified.